A pertussis-toxoid vaccine has been the subject of a placebo-controlled trial. The vaccine, known as BPZE1, has been studied for its safety, immunogenicity, and efficacy in various models, including human and animal trials. Research on the vaccine's effects and the broader context of pertussis prevention is ongoing, with studies examining immune responses, colonization, and prevention strategies.